By Fisentzos Stylianou, PhD; Senior Analyst The UK will be the first country to introduce a regulatory framework for innovative medicines manufactured at the point
By Fisentzos Stylianou, PhD; Senior Analyst Contact: [email protected] “I can say on behalf of the G-BA that it is possible that we will recognise some
By Fisentzos Stylianou, PhD Contact: [email protected] NICE’s launches a real-world evidence framework Closing knowledge gaps and advancing patient access to innovations are major aims of the
By Chloe Sheppard, Senior Analyst & Max Rex, Consultant Email: [email protected] [email protected] Cost-effectiveness analyses, as part of Health Technology Assessments (HTAs) for new therapies, appear
Leading specialist market access consultancy Partners4Access (P4A) is to host a free webinar to share insights on key 2021 trends in market access for pharma/biotech
Leading specialist market access consultancy Partners4Access (P4A) has announced it will share insights on gene therapy access for rare diseases at the biotech industry conference
By Joanna Fernandes, Associate Consultant Email: [email protected] Cell and gene therapies (CGTs) are considered one-time transformative treatments, positioned as having life-long benefits. These new therapies
Partners4Access has announced their gold sponsorship of the biotech industry conference World Orphan Drug Congress (WODC) USA. The event will take place at The Gaylord
Sophie Schmitz, Managing Partner of Partners4Access is to lead two educational sessions on gene therapy at the Academy of Managed Care Pharmacy (AMCP)’s annual meeting
